Avertissement: Ce site agrège des données publiques officielles provenant de la FDA, ClinicalTrials.gov, PubMed et SEC EDGAR à titre de référence générale uniquement. Il ne constitue pas un avis médical, un diagnostic, une recommandation de traitement ni un conseil en investissement.

PubMed

Is the current regulatory framework for direct-to-consumer microbiome-based tests sufficient to protect consumers from medical, economic, and dignitary harms?

PMID : 41450770 ·

D, i, a, n, e, , E, , H, o, f, f, m, a, n, n, ;, , F, e, l, i, c, i, a, , D, , L, a, n, g, e, l, ;, , E, r, i, k, , C, , v, o, n, , R, o, s, e, n, v, i, n, g, e, ;, , F, r, a, n, c, i, s, , B, , P, a, l, u, m, b, o, ;, , M, a, r, y, -, C, l, a, i, r, e, , R, o, g, h, m, a, n, n, ;, , J, a, c, q, u, e, s, , R, a, v, e, l

RevueJournal of law and the biosciences
Année
PMID41450770

Résumé

This article offers a thorough analysis of an important public health issue-the lack of regulation of companies selling direct-to-consumer (DTC) microbiome-based tests. These companies invite curious consumers and desperate patients to submit stool and/or vaginal secretion samples to them for analysis. Purchasers receive a report about the composition of their gut and/or vaginal microbiomes with recommendations to change their diet or take certain dietary supplements. The piece is grounded in a

Source officielle

Voir sur PubMed →

Données issues de PubMed / NCBI. Pour le texte intégral et les informations les plus récentes, consultez toujours la notice officielle.

↑